Lori Church, MD
Family Medicine · Johnson City, TNNPI 1164466827
Payments from drug & device makers
Across 301 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$896
- GSK$873
- Lilly USA, LLC$602
- Boehringer Ingelheim$426
- Novo Nordisk$357
- plus $630 from 17 others
What the payments were for
- Food & beverage$5,250100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 66 | $1,481 |
| AbbVie(2 entities) | 62 | $896 |
| GSK | 61 | $873 |
| Lilly USA, LLC | 38 | $602 |
| Boehringer Ingelheim | 23 | $426 |
| Novo Nordisk | 13 | $357 |
| Novartis | 5 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $93 |
| Pfizer | 7 | $88 |
| Amgen | 4 | $56 |
| Johnson & Johnson | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 3 | $35 |
| Seqirus USA Inc | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,265 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 145 | $186,276 |
| OzempicSemaglutide | 88 | $158,587 |
| EliquisApixaban | 118 | $132,686 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $68,753 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $50,037 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $45,502 |
| LinzessLinaclotide | 29 | $42,469 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $40,604 |
| JardianceEmpagliflozin | 19 | $30,963 |
| TrintellixVortioxetine Hydrobromide | 24 | $29,636 |
| XareltoRivaroxaban | 29 | $25,029 |
| TrulicityDulaglutide | 16 | $19,599 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $18,121 |
| FarxigaDapagliflozin Propanediol | 16 | $16,314 |
| ProliaDenosumab | 11 | $15,727 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $602 | $205,875161 claims |
| Novo NordiskOzempic | $357 | $158,58788 claims |
| PfizerEliquis | $88 | $132,686118 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix | $873 | $124,757191 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Farxiga | $1,481 | $79,93796 claims |
| AbbVieLinzess, Ubrelvy, Synthroid | $896 | $56,51162 claims |
| Boehringer IngelheimJardiance | $426 | $30,96319 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $93 | $29,63624 claims |
| Johnson & JohnsonXarelto | $38 | $25,02929 claims |
| AmgenProlia | $56 | $15,72711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Johnson City
- Jeffrey HoplandJohnson City$802K
- Leigh JohnsonJohnson City$30K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.